Kim Min Suk, Lee Soo-Yong, Cho Wan Hyeong, Song Won Seok, Koh Jae-Soo, Lee Jun Ah, Yoo Ji Young, Jung Sung Taek, Jeon Dae-Geun
Department of Pathology, Korea Cancer Center Hospital, Seoul, Korea.
J Orthop Sci. 2009 May;14(3):292-7. doi: 10.1007/s00776-009-1334-y. Epub 2009 Jun 5.
We assessed volume changes after neoadjuvant chemotherapy and evaluated relations between tumor size changes and clinical characteristics. In addition, we sought to determine whether tumor size change influences patient outcome.
The records of 127 patients with stage II osteosarcoma who showed more than a 15% volume change after chemotherapy were retrospectively reviewed. Patients were divided into two groups depending on whether tumors increased or decreased in size. Fisher's exact test was performed to analyze correlations between tumor size changes and clinicopathological variables. Five-year metastasis-free survival and overall survival were evaluated using univariate and multivariate analyses.
A total of 71 patients (55.9%) showed a decrease in tumor volume, and 56 patients (44.1%) showed an increase. An increase in tumor volume after neoadjuvant chemotherapy was found to be positively correlated with a poor histological response and subsequent metastasis. Univariate analysis identified the following parameters as poor prognostic factors: age < or = 15 years (P = 0.03), American Joint Committee on Cancer (AJCC) stage IIB (P = 0.02), a subtype other than osteoblastic (P < 0.01), a poor histological response (P < 0.001), and increased tumor volume after preoperative chemotherapy (P < 0.0001). Multivariate analysis revealed that AJCC stage IIB (P = 0.006) and an increase in tumor volume after preoperative chemotherapy (P < 0.001) both independently shortened metastasis-free survival. However, a poor histological response lost its prognostic significance (P = 0.34).
Increased tumor volume after neoadjuvant chemotherapy independently shortened metastasis-free and overall survival in AJCC stage II osteosarcoma patients. Tumor volume changes may serve as a basis for risk-adapted therapy when used in combination with other prognostic factors.
我们评估了新辅助化疗后的体积变化,并评估了肿瘤大小变化与临床特征之间的关系。此外,我们试图确定肿瘤大小变化是否会影响患者的预后。
回顾性分析了127例II期骨肉瘤患者的记录,这些患者化疗后体积变化超过15%。根据肿瘤大小是增加还是减少,将患者分为两组。采用Fisher精确检验分析肿瘤大小变化与临床病理变量之间的相关性。使用单因素和多因素分析评估5年无转移生存率和总生存率。
共有71例患者(55.9%)肿瘤体积减小,56例患者(44.1%)肿瘤体积增大。发现新辅助化疗后肿瘤体积增加与组织学反应差及随后的转移呈正相关。单因素分析确定以下参数为不良预后因素:年龄≤15岁(P = 0.03)、美国癌症联合委员会(AJCC)IIB期(P = 0.02)、非成骨细胞亚型(P < 0.01)、组织学反应差(P < 0.001)以及术前化疗后肿瘤体积增加(P < 0.0001)。多因素分析显示,AJCC IIB期(P = 0.006)和术前化疗后肿瘤体积增加(P < 0.001)均独立缩短无转移生存期。然而,组织学反应差失去了其预后意义(P = 0.34)。
新辅助化疗后肿瘤体积增加独立缩短了AJCC II期骨肉瘤患者的无转移生存期和总生存期。当与其他预后因素结合使用时,肿瘤体积变化可作为风险适应性治疗的依据。